Dermatology

ARS gears up for neffy US approval

ARS Pharmaceuticals expects to launch neffy (epinephrine nasal spray) in H2 2024, for which the company plans to submit a…

FDA approves Boehringer’s SPEVIGO for psoriasis treatment

The US Food and Drug Administration (FDA) has granted approval for Boehringer Ingelheim's SPEVIGO injection to treat generalised pustular psoriasis…

China NMPA approves KeChow’s tunlametinib for melanoma

The China National Medical Products Administration (NMPA) has approved KeChow Pharma's tunlametinib (HL-085) for treating patients with neuroblastoma ras viral…

Almirall to license Eloxx’s ZKN-013 for rare skin conditions

Almirall has signed an exclusive licence agreement to gain worldwide rights for Eloxx Pharmaceuticals’ ZKN-013 for rare dermatological disease indications.…

Galderma sets price range for supersized $2.6bn IPO in Europe

Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on…

Sanofi’s amlitelimab shows best-in-class response in atopic dermatitis 

Sanofi has announced encouraging findings from the second part of a study with the OX40 antibody amlitelimab, which showed sustained…

Almirall licenses IL-21 antibody from Novo Nordisk

Almirall has signed an exclusive licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s interleukin-21 (IL-21)-hindering monoclonal antibody,…

Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan

Sanofi and Regeneron Pharmaceuticals have received yet another approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for…

Alys Pharmaceuticals announces launch with $100m funding

Alys Pharmaceuticals has announced its launch with a research and development (R&D) immuno-dermatology focused pipeline backed by a $100m financing…

Almirall and Microsoft partner for dermatological drug development

Pharmaceutical company Almirall has entered a strategic collaboration with Microsoft to steer innovation and digital transformation in dermatology. The three-year…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close